Air Pollution and COPD Exacerbation (BePoPi)

Impact of Air Pollution on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Haut de France. BePoPi Project.

There is an excess of hospitalization rates for acute exacerbation of COPD in Picardy compared to the national data. A first study realized in Picardy has shown a link between air quality and COPD. Nevertheless, the particles type is unknown and according to it, impact on COPD could be different. The investigator goal is to find a correlation between acute exacerbation of COPD consultation rate and daily ultra thin particles in Haut de France. The investigators will correlate the particles composition with daily acute exacerbation of COPD rate. All COPD patients with a diagnosis of acute exacerbation in emergency room in University Hospital of Amiens-Picardie and Lille, and Clinique de l'Europe between 01/01/2020 and 31/12/2020 will be included. For each patient, home and work address will be collected. The duration of 1 year was chosen to take into account seasonal variations. In parallel, a daily report of the rate of ozone, particles (PM2.5 and PM10), dioxide nitrogen but also odours and pollens will be done by ATMO Haut de France.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease; Pollution; Exposure
• Intervention / Treatment: Other: collection of data about each acute exacerbation of COPD

• Study Type: Observational
• Enrollment (Actual): 120

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80480
    • CHU Amiens

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All COPD patients with a diagnosis of acute exacerbation in emergency room in University Hospital of Amiens-Picardie and Lille, and Clinique de l'Europe between 01/01/2020 and 31/12/2020 will be included. Home and work address and spirometric data will be collected. Atmo Hauts-de-France will collect daily data on PM10, PM2,5, NO2 et O3 in Amiens and Lille metropoles. Odours and pollens will be collected too by ATMO Haut de France.

Description

Inclusion Criteria:

• COPD patients with a diagnosis of acute exacerbation of COPD in the emergency room of Amiens and Lille centers
• Adults
• Patients able to express consent
• signed written informed consent form
• covered by national health insurance

Exclusion Criteria:

• patients non covered by national health insurance
• patients not able to express consent
• minors

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
daily rate of COPD exacerbation consultation in the emergency room of the 3 centers	daily rate of COPD exacerbation consultation in the emergency room of the 3 centers	every day during 12 months
ultrathin particles quantity in the air	ultrathin particles quantity will be determined by the air of "Haut de France" by the company ATMO Haut de France.	every day during 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
chemical composition ultrathin particles	chemical composition ultrathin particles will be determined by the air of "Haut de France" by the company ATMO Haut de France.	every day during 12 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens
• Collaborators: University Hospital, Lille; Clinique de l'Europe, Amiens
• Investigators: Principal Investigator: Claire Andrejak, Pr, CHU Amiens; Principal Investigator: Damien BASILLE, MD, CHU Amiens; Principal Investigator: Vincent Jounieaux, Pr, CHU Amiens; Principal Investigator: Nicolas Benoit, MD, Clinique de l'Europe, Amiens; Principal Investigator: Youcef Douadi, MD, Clinique de l'Europe, Amiens; Principal Investigator: Olivier Le Rouzic, MD, CHRU Lille

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2020
• Primary Completion (Actual): March 12, 2022
• Study Completion (Actual): September 12, 2023

Study Registration Dates

• First Submitted: April 4, 2019
• First Submitted That Met QC Criteria: April 4, 2019
• First Posted (Actual): April 5, 2019

Study Record Updates

• Last Update Posted (Actual): September 13, 2023
• Last Update Submitted That Met QC Criteria: September 12, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Chronic Obstructive Pulmonary Disease; pollution; ultrathin particles
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Disease Attributes; Chronic Disease; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: PI2019_843_0008

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No